ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2472

The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis

Maria Rydholm1,2, Ingegerd Wikström1,2, Sofia Hagel3, Lennart Jacobsson4 and Carl Turesson1,2, 1Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 4Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, grip strength, pain and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated in many patients. The objective of this study was to identify early predictors of future grip strength in patients with RA.

Methods: An inception cohort of patients with early RA (symptom duration ≤12 months), recruited in 1995-2005, was investigated and followed in a structured program (4 examinations over 5 years), including clinical evaluation and grip force measurement. Grip force was measured using the electronic instrument Grippit (AB Detektor, Gothenburg, Sweden). Average grip force values of the dominant hand were evaluated at each visit, and compared to the expected, based on age- and sex-specific reference values from the literature. Patients in each of the three higher quartiles of baseline disease activity (DAS28), disability (HAQ), pain (visual analogue scale, VAS) and patient global assessment (VAS global) were compared to the lowest quartile. Differences in percentage of expected grip force values over the study period, and differences in change over time, were estimated using mixed linear effect models.

Results: A total of 233 patients with early RA (70 % women, mean age 60.5 years, median symptom duration 7 months) were investigated. The mean value for the average grip force of the dominant hand increased from 40 % of expected at baseline to 57 % at the 5-year follow-up. Patients with baseline parameters in the three higher quartiles had significantly lower mean grip force values over time, compared to the lowest quartiles (Table). Patients in the highest quartile of DAS28 had significantly greater improvement compared to the lowest quartile (estimated difference in change per year 3.1 % of expected; 95 % CI 1.4 to 4.9). By contrast, there was no difference in improvement for those in the highest quartiles of VAS pain (estimated difference in change per year 0.5 % of expected; 95 % CI -1.3 to 2.3) or VAS global (Table), compared to those in the lowest quartiles.

Conclusion: Patients with a severe disease phenotype at baseline had particularly impaired grip force over the first 5 years after RA diagnosis. However, those with high initial disease activity experienced greater improvement in grip force, likely due to successful treatment. By contrast, poor patient reported outcomes at baseline were associated with persistent impairment of grip strength.

 



Disclosure: M. Rydholm, None; I. Wikström, None; S. Hagel, None; L. Jacobsson, None; C. Turesson, None.

To cite this abstract in AMA style:

Rydholm M, Wikström I, Hagel S, Jacobsson L, Turesson C. The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-disease-activity-and-patient-reported-outcomes-on-grip-force-over-time-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-disease-activity-and-patient-reported-outcomes-on-grip-force-over-time-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology